AstraZeneca Buys Pearl Therapeutics for GBP$740M

Company News

AstraZeneca (LSE:AZN) will pay Pearl Therapeutics, a private company based in California, 740 million British pounds for control of the company focused on developing inhaled drugs for respiratory diseases, the Daily Mail reported.

AstraZeneca (LSE:AZN) will pay Pearl Therapeutics, a private company based in California, 740 million British pounds for control of the company focused on developing inhaled drugs for respiratory diseases, the Daily Mail reported.

As quoted in the market news:

The proposed deal is worth up to $1.15bn (£740m) and is due to complete in the third quarter.

Click here for the full Daily Mail news story

The Conversation (0)
×